Bristol-Myers Squibb and Sanofi’s Plavix was the top-selling drug in the first quarter of 2012, but it’s time on top may not last long. Bristol-Myers Squibb and Sanofi’s Plavix was the top-selling ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

Aspirin is considered the cornerstone of secondary prevention of coronary artery disease. However, the evidence supporting aspirin was largely generated before the advent of modern pharmacological and ...

CHICAGO (Reuters) - A common gene variation explains why many people are not helped by the widely prescribed blood thinner Plavix, U.S. researchers said on Tuesday in a study confirming earlier ...

HONOLULU — Pharmaceutical companies have agreed to pay Hawaii $700 million to settle its lawsuit over the efficacy and safety of the blood thinner Plavix, the state attorney general's office announced ...

BARCELONA (Reuters) - AstraZeneca's new pill Brilinta for preventing heart attacks works better than Plavix, the world's second biggest selling drug, without increasing the amount of life-threatening ...

This year, Peter R. Dolan, the CEO of Bristol-Myers Squibb, was faced with the threat of generic competition for Plavix, an anti-clotting drug with $3.2 billion in annual U.S. sales. In responding to ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. HONOLULU (AP) — Pharmaceutical companies ...